GoAI
Get started
SeaStar Medical Holding Corporation logo

SeaStar Medical Holding Corporation

ICU

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.35

+$0.01 · +0.30%

Aug 21, 4:00 PM ET

ICU company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

69

Undervalued

Momentum

64

Gaining

Sentiment

59

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Eric Schlorff
Listed since
Mar 18, 2021
Employees
18

Market position

Day range

Current $3.35

52-week range

Current $3.35

Open
$3.32
Previous close
$3.34
Volume
68.76K
0.77× average
Average volume
88.99K
Average daily volume
Market cap
9.51M USD
Beta
-1.04
Market reference 1
50-day average
$3.6637
-8.56% below average
200-day average
$3.3419
+0.24% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
38.3M USD
P/E (TTM)
-0.86×
P/B (TTM)
3.18×
P/S (TTM)
5.55×
EV / EBITDA
-3.15×
Earnings yield
-24.42%
Free cash flow yield
-27.33%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
92.64%
Operating margin
-816.64%
Net margin
-795.50%
Return on equity
-116.65%
Return on assets
-85.82%
Return on invested capital
-111.28%

Financial health

Debt / equity
0×
Current ratio
3.63×
Altman Z-score
-28.91
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1949%-5448%-12845%-20242%Gross margin, FY2024: 100.00%Gross margin, FY2025: 95.71%Operating margin, FY2024: -13216.30%Operating margin, FY2025: -986.63%Net margin, FY2024: -18392.59%Net margin, FY2025: -984.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 95.71%. Operating margin FY2024 -13216.30%. Operating margin FY2025 -986.63%. Net margin FY2024 -18392.59%. Net margin FY2025 -984.60%.

Income trends

Revenue

1.23M USD+814.07%

Operating income

−12.18M USD+31.76%

Net income

−12.15M USD+51.07%
Income trends across reported periods3.98M USD−7.01M USD−17.99M USD−28.98M USDRevenue, FY2024: 135K USDRevenue, FY2025: 1.23M USDOperating income, FY2021: −4.45M USDOperating income, FY2022: −11.61M USDOperating income, FY2023: −14.21M USDOperating income, FY2024: −17.84M USDOperating income, FY2025: −12.18M USDNet income, FY2021: −4.6M USDNet income, FY2022: −12.19M USDNet income, FY2023: −26.23M USDNet income, FY2024: −24.83M USDNet income, FY2025: −12.15M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 135K USD. Revenue FY2025 1.23M USD. Operating income FY2021 −4.45M USD. Operating income FY2022 −11.61M USD. Operating income FY2023 −14.21M USD. Operating income FY2024 −17.84M USD. Operating income FY2025 −12.18M USD. Net income FY2021 −4.6M USD. Net income FY2022 −12.19M USD. Net income FY2023 −26.23M USD. Net income FY2024 −24.83M USD. Net income FY2025 −12.15M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.23M USD135K USD———
Cost of goods sold53K USD————
Gross profit1.18M USD135K USD———
Research and development7.52M USD9.11M USD5.97M USD2.5M USD2.77M USD
Selling, general, and administrative5.84M USD8.87M USD8.04M USD6.92M USD1.68M USD
Operating expenses13.36M USD17.98M USD14.21M USD11.61M USD4.45M USD
Interest income325K USD101K USD—630 USD—
Interest expense329K USD244K USD1.08M USD630K USD212K USD
Depreciation and amortization18K USD—14.01M USD——
Operating income−12.18M USD−17.84M USD−14.21M USD−11.61M USD−4.45M USD
Net income−12.15M USD−24.83M USD−26.23M USD−12.19M USD−4.6M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+3.90%
11 comparable reports
Latest EPS result
-0.91
Estimate -0.97 · Beat by 6.19%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.62-3.63-6.65-9.66Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -9, estimate -8.9, surprise -1.12%, Miss. Q2 2025, reported May 14, 2025: actual -4.4, estimate -5.2, surprise +15.38%, Beat. Q3 2025, reported Aug 13, 2025: actual -1.8, estimate -4.3, surprise +58.14%, Beat. Q4 2025, reported Nov 13, 2025: actual -1.3, estimate -1.5, surprise +13.33%, Beat. Q1 2026, reported Mar 25, 2026: actual -0.8, estimate -0.97, surprise +17.53%, Beat. Q2 2026, reported May 13, 2026: actual -0.9, estimate -0.73, surprise -23.29%, Miss. Q3 2026, reported Aug 12, 2026: actual -0.91, estimate -0.97, surprise +6.19%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.95, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates658.84K458.21K257.58K56.95KQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual 67K USD, estimate 150K USD, surprise -55.33%, Miss. Q2 2025, reported May 14, 2025: actual 293K USD, estimate 150K USD, surprise +95.33%, Beat. Q3 2025, reported Aug 13, 2025: actual 338K USD, estimate 200K USD, surprise +69.00%, Beat. Q4 2025, reported Nov 13, 2025: actual 183K USD, estimate 250K USD, surprise -26.80%, Miss. Q1 2026, reported Mar 25, 2026: actual 420K USD, estimate 222.5K USD, surprise +88.76%, Beat. Q2 2026, reported May 13, 2026: actual 495K USD, estimate 437.5K USD, surprise +13.14%, Beat. Q3 2026, reported Aug 12, 2026: actual 615K USD, estimate 486.5K USD, surprise +26.41%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 500K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$8.00

138.81% upside
Past 12 months12-month forecastHigh $8.00Average $8.00Low $8.00

Recent analyst actions

1 institution
Maxim GroupmaintainBuy

ICU news

seekingalpha.com

SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript

SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

Added 3 top-rated children's hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025

Read source
benzinga.com

ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings

ICU Medical Inc (NASDAQ:ICUI) on Thursday posted upbeat earnings for the second quarter.

Read source
marketbeat.com

ICU Medical Q2 Earnings Call Highlights

ICU Medical NASDAQ: ICUI reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis, as growth in its consumables and infusion systems businesses helped offset continued pressure in…

Read source
globenewswire.com

ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance

SAN CLEMENTE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the…

Read source
globenewswire.com

SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026

DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jan 5, 2026

1:10

Stock split

Effective Jun 10, 2024

1:25

ICU peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ICU

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
103.57K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Dimensional - US Core Equity 2 ETF logoDimensional - US Core Equity 2 ETFDFAC
Market value
9.5K
Weight
0.00%
AUM
49.31B USD
Expense ratio
0.17%
Price / 1D
$45.61+0.46%

Continue in GoAI

Research ICU

research.disclaimer